US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Nutriband Inc. - Common Stock (NQ:NTRB)

7.280 -0.080 (-1.09%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nutriband Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Nutriband Inc. (NASDAQ: NTRB) Reports Double-Digit Revenue Increase, Continued Progress on AVERSA Fentanyl Development
Via Investor Brand Network
Topics Intellectual Property
BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Secures U.S. Patent for Abuse-Deterrent Transdermal Technology
Via Investor Brand Network
Topics Intellectual Property
News headline image
Nutriband Announces U.S. Patent Issued for Its Transdermal Abuse Deterrent Technology
From Nutriband Inc.
Via GlobeNewswire
Nutriband Inc. (NASDAQ: NTRB) Advances Abuse-Deterrent Buprenorphine Therapy with AVERSA Technology
Via Investor Brand Network
Nutriband Inc. (NASDAQ: NTRB): A Relentless Mission Rooted in Purpose, Innovation, and Shareholder Value
Via Investor Brand Network
Topics Initial Public Offering
BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) to Present at Noble Capital Markets Emerging Growth Virtual Conference
Via Investor Brand Network
News headline image
Nutriband Inc. to present at the 2025 Noble Capital Markets Virtual Equity Conference
From Nutriband Inc.
Via GlobeNewswire
BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Posts Record Q1 Revenue, Advances AVERSA Fentanyl Development
Via Investor Brand Network
News headline image
Nutriband Inc. Quarterly Report Highlights Record Revenue for Q1, 2025 up 63% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl
From Nutriband Inc.
Via GlobeNewswire
BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) CEO Highlights Transdermal Pain Solution on BioMedWire Podcast
Via Investor Brand Network
Nutriband Inc. (NASDAQ: NTRB) Charts Path to Commercialization
Via Investor Brand Network
BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Strengthens Pharma Footprint Through Key Alliances
Via Investor Brand Network
Topics Artificial Intelligence
Nutriband Inc. (NASDAQ: NTRB) Pioneers Innovative Approach to Opioid Crisis with Game-Changing Transdermal Patch
Via Investor Brand Network
Nutriband Inc. (NASDAQ: NTRB) Innovating Abuse-Deterrent Drug Delivery in a Shifting Opioid Landscape
Via Investor Brand Network
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) CEO Issues Shareholder Letter Highlighting 2024 Milestones and 2025 Commercialization Goals
Via Investor Brand Network
Topics Intellectual Property
Nutriband Inc. (NASDAQ: NTRB) Leadership Team: Driving Innovation and Shaping the Future of Global Healthcare
Via Investor Brand Network
News headline image
Nutriband CEO Publishes Letter to Shareholders
From Nutriband Inc.
Via GlobeNewswire
Nutriband Inc. (NASDAQ: NTRB) Solution To Fentanyl Abuse Could Translate To $200 Million In Peak Revenue
Via AB Newswire
Topics Intellectual Property
News headline image
Nutriband Inc (NASDAQ: NTRB) Solution To Fentanyl Abuse Could Translate To $200 Million In Peak Revenue
Nutriband Inc (NASDAQ: NTRB) Solution To Fentanyl Abuse Could Translate To $200 Million In Peak Revenue 
Via News Direct
Topics Intellectual Property
BioMedNewsBreaks — Why Nutriband Inc. (NASDAQ: NTRB) Is ‘One to Watch’
Via Investor Brand Network
Topics Intellectual Property
Nutriband Inc. (NASDAQ: NTRB): Building a Moat Around Abuse-Deterrent Drug Delivery
Via Investor Brand Network
Topics Intellectual Property
News headline image
BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) CEO Named EY Entrepreneur of the Year 2025 Finalist in Established Category
Via Investor Brand Network
News headline image
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Secures Patent in Macao for AVERSA Abuse-Deterrent Technology
Via Investor Brand Network
Topics Intellectual Property
News headline image
Nutriband Granted Patent in Macao for its AVERSA Abuse Deterrent Transdermal Technology
Nutriband granted patent protecting its AVERSA abuse deterrent platform technology in Macao, a Special Administrative Region of the People’s Republic of China 
From Nutriband Inc.
Via GlobeNewswire
News headline image
UPDATE – Nutriband Signs Associate Partnership with Charlotte FC
From Nutriband Inc.
Via GlobeNewswire
News headline image
BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Signs Partnership Deal With Charlotte FC to Boost Brand Visibility
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Nutriband Signs Partnership Agreement with Charlotte FC
From Nutriband Inc.
Via GlobeNewswire
News headline image
Stock Market Indices Suffer Significant Trend Change Following Friday's Session ↗
In this video, I review the market warnings I've shared over the past three weeks and how Friday's session confirmed negative divergences across key metrics signaling weakness. 
Via Talk Markets
Topics ETFs Stocks / Equities
News headline image
Nutriband Receives Certificate of Registration for Trademark covering Pharmaceutical and Product Research and Development.
From Nutriband Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >